{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:10:09Z","timestamp":1792026609932,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Older patients with diabetes often require multiple medications to manage complications, and have a high risk of potentially inappropriate medications (PIMs). Given limited information regarding diabetes-specific PIMs, we characterized PIM prescriptions in older patients with and without type 1 or 2 diabetes, and examined gender differences in diabetes-specific PIMs, using pharmacy claims data obtained from nationwide branches of a chain pharmacy company in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pharmacy claims data of patients aged 65 years and over who used one of the 905 community-based pharmacy branches of Sugi Pharmacy Co., Ltd. during a month were anonymized and analyzed. The enrolled individuals were separated to diabetic and non-diabetic groups on the basis of anti-diabetic medications. The two groups were balanced for the age, gender ratio, and status of home healthcare insurance application through propensity score matching (PSM). PIMs, i.e. medications prone to cause adverse reactions and replaceable with others, were classified to twelve categories other than anti-diabetic PIMs, and the incidence of each PIM category in diabetic and non-diabetic groups was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 333,869 older patients, 37,606 received anti-diabetic medications. Analysis of pharmacy claims data after PSM showed that aged individuals with diabetes had significant increases in the number of medications and the incidence of PIMs, compared to individuals without diabetes. Multivariate logistic regression analyses indicated that older individuals with diabetes had significantly increased incidences of six PIM categories, sleeping drugs, \u03b1-adrenoceptor blockers, H\n                      <jats:sub>2<\/jats:sub>\n                      -blockers, drugs for overactive bladder, diuretic drugs, and concomitant intake of multiple antithrombotic drugs. Sub-group analyses of each gender data detected a diabetes-related significant increase in the incidence of the PIM category of drugs for overactive drugs in older females, but not males [adjusted odds ratios (95% confidence interval): 1.59 (1.35\u20131.88) and 0.91 (0.77\u20131.08), respectively], while significantly increased incidences of the residual five PIM categories in the diabetic group were detected regardless gender.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Older individuals with diabetes had higher risks of five PIM categories regardless of gender, and of one female-specific PIM category, than individuals without diabetes. These findings are helpful for pharmacists to make recommendations of deprescribing PIMs in pharmaceutical care of older patients with diabetes Geriatrics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-025-00505-7","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:52:10Z","timestamp":1762959130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of potentially inappropriate medications characteristic of older individuals with diabetes: a study using pharmacy claims data"],"prefix":"10.1186","volume":"11","author":[{"given":"Takashi","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Kasanami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumio","family":"Matzno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsufumi","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"505_CR1","doi-asserted-by":"publisher","first-page":"1118848","DOI":"10.3389\/fendo.2023.1118848","volume":"14","author":"P Majety","year":"2023","unstructured":"Majety P, Lozada Orquera FA, Edem D, Hamdy O. Pharmacological approaches to the prevention of type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023;14:1118848. https:\/\/doi.org\/10.3389\/fendo.2023.1118848.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"505_CR2","doi-asserted-by":"publisher","unstructured":"Sharma R, Chhabra M, Vidyasagar K, Rashid M, Fialova D, Bhagavathula AS. Potentially inappropriate medication use in older hospitalized patients with type 2 diabetes: a cross-sectional study. Pharm (Basel). 2020;8. https:\/\/doi.org\/10.3390\/pharmacy8040219.","DOI":"10.3390\/pharmacy8040219"},{"key":"505_CR3","doi-asserted-by":"publisher","unstructured":"By the American Geriatrics Society Beers Criteria Update Expert P. American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227-46. https:\/\/doi.org\/10.1111\/jgs.13702","DOI":"10.1111\/jgs.13702"},{"key":"505_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5414\/cpp46072","volume":"46","author":"P Gallagher","year":"2008","unstructured":"Gallagher P, Ryan C, Byrne S, Kennedy J, O\u2019Mahony D. STOPP (Screening tool of older person\u2019s Prescriptions) and START (Screening tool to alert Doctors to right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72\u201383. https:\/\/doi.org\/10.5414\/cpp46072.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"505_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/ggi.12890","volume":"16","author":"T Kojima","year":"2016","unstructured":"Kojima T, Mizukami K, Tomita N, Arai H, Ohrui T, Eto M, et al. Screening tool for older persons\u2019 appropriate prescriptions for japanese: report of the Japan geriatrics society working group on guidelines for medical treatment and its safety in the elderly. Geriatr Gerontol Int. 2016;16:983\u20131001. https:\/\/doi.org\/10.1111\/ggi.12890.","journal-title":"Geriatr Gerontol Int"},{"key":"505_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ggi.13850","volume":"20","author":"R Hashimoto","year":"2020","unstructured":"Hashimoto R, Fujii K, Shimoji S, Utsumi A, Hosokawa K, Tochino H, et al. Study of pharmacist intervention in polypharmacy among older patients: Non-randomized, controlled trial. Geriatr Gerontol Int. 2020;20:229\u201337. https:\/\/doi.org\/10.1111\/ggi.13850.","journal-title":"Geriatr Gerontol Int"},{"key":"505_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40545-023-00621-5","volume":"16","author":"CT Chang","year":"2023","unstructured":"Chang CT, Teoh SL, Cheah WK, Lee PJ, Azman MA, Ling SH, et al. Impact of deprescribing intervention on potentially inappropriate medications and clinical outcomes among hospitalized older adults in malaysia: a randomized controlled trial (REVMED RCT) protocol. J Pharm Policy Pract. 2023;16:113. https:\/\/doi.org\/10.1186\/s40545-023-00621-5.","journal-title":"J Pharm Policy Pract"},{"key":"505_CR8","doi-asserted-by":"publisher","first-page":"105122","DOI":"10.1016\/j.jamda.2024.105122","volume":"25","author":"E Hurley","year":"2024","unstructured":"Hurley E, Dalton K, Byrne S, Foley T, Walsh E. Pharmacist-Led deprescribing using STOPPFrail for frail older adults in nursing homes. J Am Med Dir Assoc. 2024;25:105122. https:\/\/doi.org\/10.1016\/j.jamda.2024.105122.","journal-title":"J Am Med Dir Assoc"},{"key":"505_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s00508-020-01801-y","volume":"133","author":"M Stuhec","year":"2021","unstructured":"Stuhec M, Flegar I, Zelko E, Kovacic A, Zabavnik V. Clinical pharmacist interventions in cardiovascular disease pharmacotherapy in elderly patients on excessive polypharmacy: A retrospective pre-post observational multicentric study. Wien Klin Wochenschr. 2021;133:770\u20139. https:\/\/doi.org\/10.1007\/s00508-020-01801-y.","journal-title":"Wien Klin Wochenschr"},{"key":"505_CR10","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1248\/bpb.b23-00385","volume":"46","author":"Y Kasanami","year":"2023","unstructured":"Kasanami Y, Yamamoto T, Miyamoto T, Matzno S, Sakakibara M, Iwaki M, et al. Characterization of potentially inappropriate medications that need special attention in the elderly with dementia by analyzing pharmacy claims data. Biol Pharm Bull. 2023;46:1699\u2013705. https:\/\/doi.org\/10.1248\/bpb.b23-00385.","journal-title":"Biol Pharm Bull"},{"key":"505_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/dme.12894","volume":"33","author":"F Formiga","year":"2016","unstructured":"Formiga F, Vidal X, Agusti A, Chivite D, Roson B, Barbe J, et al. Inappropriate prescribing in elderly people with diabetes admitted to hospital. Diabet Med. 2016;33:655\u201362. https:\/\/doi.org\/10.1111\/dme.12894.","journal-title":"Diabet Med"},{"key":"505_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.pcd.2020.03.003","volume":"14","author":"ME Gagnon","year":"2020","unstructured":"Gagnon ME, Sirois C, Simard M, Roux B, Plante C. Potentially inappropriate medications in older individuals with diabetes: A population-based study in Quebec, Canada. Prim Care Diabetes. 2020;14:529\u201337. https:\/\/doi.org\/10.1016\/j.pcd.2020.03.003.","journal-title":"Prim Care Diabetes"},{"key":"505_CR13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s11096-022-01414-7","volume":"44","author":"MB Ayalew","year":"2022","unstructured":"Ayalew MB, Spark MJ, Quirk F, Dieberg G. Potentially inappropriate prescribing for adults living with diabetes mellitus: a scoping review. Int J Clin Pharm. 2022;44:860\u201372. https:\/\/doi.org\/10.1007\/s11096-022-01414-7.","journal-title":"Int J Clin Pharm"},{"key":"505_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41387-025-00379-6","volume":"15","author":"M Hellwig","year":"2025","unstructured":"Hellwig M, Decker J, Prates Roma L, Schunk S, Ampofo E, Rother S. Sex-specific differences of advanced glycation end products in diabetes. Nutr Diabetes. 2025;15:27. https:\/\/doi.org\/10.1038\/s41387-025-00379-6.","journal-title":"Nutr Diabetes"},{"key":"505_CR15","doi-asserted-by":"publisher","unstructured":"Merlin E, Salio C, Ferrini F. Painful diabetic neuropathy: Sex-specific mechanisms and differences from animal models to clinical outcomes. Cells. 2024;13. https:\/\/doi.org\/10.3390\/cells13232024.","DOI":"10.3390\/cells13232024"},{"key":"505_CR16","doi-asserted-by":"publisher","first-page":"e2167","DOI":"10.1210\/clinem\/dgae655","volume":"109","author":"ES LeBlanc","year":"2024","unstructured":"LeBlanc ES, Brooks N, Davies M, Chatterjee R. Sex-Specific cardiovascular risk factors and treatment in females with T2DM and CVD: developments and knowledge gaps. J Clin Endocrinol Metab. 2024;109:e2167\u201377. https:\/\/doi.org\/10.1210\/clinem\/dgae655.","journal-title":"J Clin Endocrinol Metab"},{"key":"505_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bph.12362","volume":"171","author":"F Franconi","year":"2014","unstructured":"Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014;171:580\u201394. https:\/\/doi.org\/10.1111\/bph.12362.","journal-title":"Br J Pharmacol"},{"key":"505_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143\u201357. https:\/\/doi.org\/10.2165\/00003088-200948030-00001.","journal-title":"Clin Pharmacokinet"},{"key":"505_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11:32. https:\/\/doi.org\/10.1186\/s13293-020-00308-5.","journal-title":"Biol Sex Differ"},{"key":"505_CR20","doi-asserted-by":"publisher","first-page":"e037528","DOI":"10.1136\/bmjopen-2020-037528","volume":"10","author":"S Ida","year":"2020","unstructured":"Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, et al. Factors associated with social isolation and being homebound among older patients with diabetes: a cross-sectional study. BMJ Open. 2020;10:e037528. https:\/\/doi.org\/10.1136\/bmjopen-2020-037528.","journal-title":"BMJ Open"},{"key":"505_CR21","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.2337\/diacare.28.11.2613","volume":"28","author":"G Bruno","year":"2005","unstructured":"Bruno G, Runzo C, Cavallo-Perin P, Merletti F, Rivetti M, Pinach S, et al. Incidence of type 1 and type 2 diabetes in adults aged 30\u201349 years: the population-based registry in the Province of Turin, Italy. Diabetes Care. 2005;28:2613\u20139. https:\/\/doi.org\/10.2337\/diacare.28.11.2613.","journal-title":"Diabetes Care"},{"key":"505_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s001250051573","volume":"44","author":"EA Gale","year":"2001","unstructured":"Gale EA, Gillespie KM. Diabetes and gender. Diabetologia. 2001;44:3\u201315. https:\/\/doi.org\/10.1007\/s001250051573.","journal-title":"Diabetologia"},{"key":"505_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1210\/er.2015-1137","volume":"37","author":"A Kautzky-Willer","year":"2016","unstructured":"Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in Risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev. 2016;37:278\u2013316. https:\/\/doi.org\/10.1210\/er.2015-1137.","journal-title":"Endocr Rev"},{"key":"505_CR24","doi-asserted-by":"publisher","first-page":"108078","DOI":"10.1016\/j.diabres.2020.108078","volume":"162","author":"A Sinclair","year":"2020","unstructured":"Sinclair A, Saeedi P, Kaundal A, Karuranga S, Malanda B, Williams R. Diabetes and global ageing among 65-99-year-old adults: findings from the international diabetes federation diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2020;162:108078. https:\/\/doi.org\/10.1016\/j.diabres.2020.108078.","journal-title":"Diabetes Res Clin Pract"},{"key":"505_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"key":"505_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1447-0594.2012.00868.x","volume":"12","author":"T Kojima","year":"2012","unstructured":"Kojima T, Akishita M, Kameyama Y, Yamaguchi K, Yamamoto H, Eto M, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int. 2012;12:761\u20132. https:\/\/doi.org\/10.1111\/j.1447-0594.2012.00868.x.","journal-title":"Geriatr Gerontol Int"},{"key":"505_CR27","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s40520-022-02165-1","volume":"34","author":"F Remelli","year":"2022","unstructured":"Remelli F, Ceresini MG, Trevisan C, Noale M, Volpato S. Prevalence and impact of polypharmacy in older patients with type 2 diabetes. Aging Clin Exp Res. 2022;34:1969\u201383. https:\/\/doi.org\/10.1007\/s40520-022-02165-1.","journal-title":"Aging Clin Exp Res"},{"key":"505_CR28","doi-asserted-by":"publisher","first-page":"1098465","DOI":"10.3389\/fphar.2023.1098465","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhu J, Shan L, Wu L, Wang C, Yang W. Potentially inappropriate medication among older patients with diabetic kidney disease. Front Pharmacol. 2023;14:1098465. https:\/\/doi.org\/10.3389\/fphar.2023.1098465.","journal-title":"Front Pharmacol"},{"key":"505_CR29","doi-asserted-by":"publisher","first-page":"1497449","DOI":"10.1155\/2021\/1497449","volume":"2021","author":"N Samsu","year":"2021","unstructured":"Samsu N. Diabetic nephropathy: challenges in Pathogenesis, Diagnosis, and treatment. Biomed Res Int. 2021;2021:1497449. https:\/\/doi.org\/10.1155\/2021\/1497449.","journal-title":"Biomed Res Int"},{"key":"505_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, Ceriello A, Ryden L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26:25\u201332. https:\/\/doi.org\/10.1177\/2047487319878371.","journal-title":"Eur J Prev Cardiol"},{"key":"505_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41574-022-00776-2","volume":"19","author":"LL Lim","year":"2023","unstructured":"Lim LL, Chow E, Chan JCN. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nat Rev Endocrinol. 2023;19:151\u201363. https:\/\/doi.org\/10.1038\/s41574-022-00776-2.","journal-title":"Nat Rev Endocrinol"},{"key":"505_CR32","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1177\/1535370216657613","volume":"241","author":"A Bickett","year":"2016","unstructured":"Bickett A, Tapp H. Anxiety and diabetes: innovative approaches to management in primary care. Exp Biol Med (Maywood). 2016;241:1724\u201331. https:\/\/doi.org\/10.1177\/1535370216657613.","journal-title":"Exp Biol Med (Maywood)"},{"key":"505_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11892-018-1055-8","volume":"18","author":"RP Ogilvie","year":"2018","unstructured":"Ogilvie RP, Patel SR. The epidemiology of sleep and diabetes. Curr Diab Rep. 2018;18:82. https:\/\/doi.org\/10.1007\/s11892-018-1055-8.","journal-title":"Curr Diab Rep"},{"key":"505_CR34","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/jdi.14168","volume":"15","author":"M Minamida","year":"2024","unstructured":"Minamida M, Okada H, Hamaguchi M, Hironaka J, Kondo Y, Nakajima H, et al. Association between Gastrointestinal symptoms and insomnia in patients with type 2 diabetes: the KAMOGAWA-DM cohort study. J Diabetes Investig. 2024;15:946\u201352. https:\/\/doi.org\/10.1111\/jdi.14168.","journal-title":"J Diabetes Investig"},{"key":"505_CR35","doi-asserted-by":"publisher","first-page":"e70036","DOI":"10.1002\/gps.70036","volume":"40","author":"Y Okita","year":"2025","unstructured":"Okita Y, Shimomura Y, Komukai S, Zha L, Komatsu M, Kimura Y, et al. Risks of dementia associated with anticholinergic medication compared to Beta-3 agonist among older patients with overactive bladder in japan: the LIFE study. Int J Geriatr Psychiatry. 2025;40:e70036. https:\/\/doi.org\/10.1002\/gps.70036.","journal-title":"Int J Geriatr Psychiatry"},{"key":"505_CR36","doi-asserted-by":"publisher","first-page":"e000799","DOI":"10.1136\/bmjmed-2023-000799","volume":"3","author":"B Iyen","year":"2024","unstructured":"Iyen B, Coupland C, Bell BG, Ashcroft DM, Orrell MW, Bishara D, et al. Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged >\/=55 years: nested case-control study. BMJ Med. 2024;3:e000799. https:\/\/doi.org\/10.1136\/bmjmed-2023-000799.","journal-title":"BMJ Med"},{"key":"505_CR37","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/1471-0528.17912","volume":"131","author":"J Park","year":"2024","unstructured":"Park J, Chang Y, Kim JH, Choi HR, Kwon R, Lim GY, et al. Menopausal stages and overactive bladder symptoms in middle-aged women: A cross-sectional study. BJOG. 2024;131:1805\u201314. https:\/\/doi.org\/10.1111\/1471-0528.17912.","journal-title":"BJOG"},{"key":"505_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.5213\/inj.2012.16.3.126","volume":"16","author":"TF Al-Shaiji","year":"2012","unstructured":"Al-Shaiji TF, Radomski SB. Relationship between body mass index and overactive bladder in women and correlations with urodynamic evaluation. Int Neurourol J. 2012;16:126\u201331. https:\/\/doi.org\/10.5213\/inj.2012.16.3.126.","journal-title":"Int Neurourol J"},{"key":"505_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2015.12.029","volume":"109","author":"F Lopez Vicchi","year":"2016","unstructured":"Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, Becu-Villalobos D. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res. 2016;109:74\u201380. https:\/\/doi.org\/10.1016\/j.phrs.2015.12.029.","journal-title":"Pharmacol Res"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00505-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00505-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00505-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:56:41Z","timestamp":1781614601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-025-00505-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["505"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00505-7","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study was in accordance with the ethical principles of the Declaration of Helsinki, and was approved by the Ethics Committees of the Faculty of Pharmacy, Kindai University (approval number 20\u2013161, April 22nd, 2020). Considering the retrospective nature of this study, the requirement for written consent was waved by employing an opt-out strategy, which was approved by the above-mentioned institutional ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}